4[1]Yonemura Y, Sugiyama K, Fushida S, et al. Treatment options for peritoneal dissemination with chemotherapy. In Yonemura Y(eds): Peritoneal dissemination——molecular mechanisms and the latest therapy. Maeda Shoten Co, Ltd Kanazawa, Japan, 1998:175.
5[2]Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon's role. Langenbecks Arch Surg, 1999, 384: 576.
6[3]Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993, 17: 256.
7[4]Yonemura Y, Matsuki N, Sakuma H, et al. Effect of intra-arterial infusion of MMC and CDDP for gastric cancer patients with liver metastasis. Jap J Surg, 1992, 22: 253.
8[5]Ohoyama S. Nakajima S. Ishihara S, et al. FLEP therapy for advanced gastric cancer. In Miyazaki I and Yonemura Y(eds): Treatment strategies for advanced gastric cancer. Soft Science. Tokyo,1995:110.
9[6]Kern W, Brasess J, Samel S, et al. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage in patients with locally advanced gastric cancer. The proceedings of 2nd International Gastric Cancer Congress. 1997: 1387.
10[7]Elias D, Detroz B, Debaeme B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia reliable and unreliable concepts. Hepatogastroenterology, 1994, 41: 207.
8Husek P. Chloroformates in gas chromatography as general purpose derivatizing agents[J]. Journal of Chromatography B ,1998,717:57-91.
9van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens[J]. Curr Opin Immunol, 1997,9:684-693.
10Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage Ⅳ melanoma[J]. J Exp Med, 1999,190:1669-1678.
